Title |
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia
|
---|---|
Published in |
Cochrane database of systematic reviews, September 2012
|
DOI | 10.1002/14651858.cd009045.pub2 |
Pubmed ID | |
Authors |
Liat Vidal, Anat Gafter‐Gvili, Ronit Gurion, Pia Raanani, Martin Dreyling, Ofer Shpilberg |
Abstract |
Indolent B cell lymphoid malignancies include follicular lymphoma, small lymphocytic lymphoma, mantle cell lymphoma, lymphoplasmacytic lymphoma and marginal zone lymphomas. Chronic lymphocytic leukaemia (CLL) is a lymphoid malignancy similar to small lymphocytic lymphoma (SLL) in its leukaemic phase.Indolent lymphoid malignancies including CLL are characterised by slow growth, a high initial response rate and a relapsing and progressive disease course. Advanced-stage indolent B cell lymphoid malignancies are often incurable. If symptoms or progressive disease occur, chemotherapy plus rituximab is indicated. No chemotherapy regimen has been shown to improve overall survival compared to a different regimen.Bendamustine is efficacious in the treatment of patients with indolent B cell lymphoid malignancies. A number of randomised controlled trials have examined the effect of bendamustine compared to other chemotherapy regimens in these patients. Improved disease control with no survival benefit is shown. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | <1% |
Switzerland | 1 | <1% |
Unknown | 115 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 14 | 12% |
Student > Bachelor | 13 | 11% |
Other | 11 | 9% |
Researcher | 11 | 9% |
Student > Ph. D. Student | 11 | 9% |
Other | 24 | 21% |
Unknown | 33 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 54 | 46% |
Nursing and Health Professions | 10 | 9% |
Psychology | 4 | 3% |
Economics, Econometrics and Finance | 3 | 3% |
Agricultural and Biological Sciences | 2 | 2% |
Other | 10 | 9% |
Unknown | 34 | 29% |